Tonix Pharmaceuticals Holding Corp. (TNXP)
7.29
+0.01
(+0.14%)
USD |
NASDAQ |
Oct 09, 16:00
7.33
+0.04
(+0.55%)
After-Hours: 20:00
Tonix Pharmaceuticals Cash from Operations (Quarterly) : -41.87M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -41.87M |
| March 31, 2026 | -42.32M |
| December 31, 2025 | -40.49M |
| September 30, 2025 | -30.51M |
| June 30, 2025 | -16.17M |
| March 31, 2025 | -16.58M |
| December 31, 2024 | -14.04M |
| September 30, 2024 | -19.98M |
| June 30, 2024 | -9.468M |
| March 31, 2024 | -17.58M |
| December 31, 2023 | -21.69M |
| September 30, 2023 | -24.53M |
| June 30, 2023 | -24.19M |
| March 31, 2023 | -32.91M |
| December 31, 2022 | -22.80M |
| September 30, 2022 | -23.25M |
| June 30, 2022 | -20.05M |
| March 31, 2022 | -31.05M |
| December 31, 2021 | -22.34M |
| September 30, 2021 | -12.53M |
| June 30, 2021 | -19.01M |
| March 31, 2021 | -21.06M |
| December 31, 2020 | -14.52M |
| September 30, 2020 | -16.50M |
| June 30, 2020 | -10.09M |
| Date | Value |
|---|---|
| March 31, 2020 | -9.326M |
| December 31, 2019 | -6.640M |
| September 30, 2019 | -6.832M |
| June 30, 2019 | -4.678M |
| March 31, 2019 | -8.639M |
| December 31, 2018 | -6.580M |
| September 30, 2018 | -4.950M |
| June 30, 2018 | -5.256M |
| March 31, 2018 | -6.771M |
| December 31, 2017 | -4.873M |
| September 30, 2017 | -4.957M |
| June 30, 2017 | -4.450M |
| March 31, 2017 | -4.794M |
| December 31, 2016 | -5.443M |
| September 30, 2016 | -8.392M |
| June 30, 2016 | -7.995M |
| March 31, 2016 | -15.48M |
| December 31, 2015 | -11.91M |
| September 30, 2015 | -12.31M |
| June 30, 2015 | -9.238M |
| March 31, 2015 | -9.053M |
| December 31, 2014 | -8.218M |
| September 30, 2014 | -4.859M |
| June 30, 2014 | -5.699M |
| March 31, 2014 | -4.064M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -18.05M |
| Nektar Therapeutics | -75.77M |
| Heron Therapeutics, Inc. | -2.213M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.5769M |
| Cash from Financing (Quarterly) | 33.27M |
| Free Cash Flow | -160.40M |
| Free Cash Flow Per Share (Quarterly) | -2.552 |
| Free Cash Flow to Equity (Quarterly) | -42.43M |
| Free Cash Flow to Firm (Quarterly) | -42.44M |
| Free Cash Flow Yield | -172.3% |